Nonhypoglycemic drug reactions of agents used to treat diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 29, Issue 4, 2000, Pages 803-811

  White, Jennifer A ^a   Hirsch, Irl B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; MEGLITINIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; EDEMA; HEART INFARCTION PREVENTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN ALLERGY; LACTIC ACIDOSIS; LIPOATROPHY; NAUSEA; PRIORITY JOURNAL; REVIEW; TASTE DISORDER;

EID: 0034541408     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70165-1     Document Type: Article

References (38)

1. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II. Mortality results
2. Hepatocellular injury in a patient receiving rosiglitazone
3. Acarbose-associated hepatoxicity
4. Hepatic injury caused by acarbose
5. The sulfonylurea controversy: More questions from the heart
6. Acarbose-induced acute severe hepatoloxicity
7. Amino acid sequences of proinsulins and intermediates
8. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus
9. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium
10. Multicenter, placebo-controlled trial comparing acerbose (BAY g5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
11. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus
12. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
13. Acarbose-induced acute hepatitis
14. Ephedrine: A new treatment for diabetic neuropathic oedema
15. Hepatic failure in a patient taking rosiglitazone
16. Acarbose-induced hepatic injury
17. The clinical use of insulin and the complications of insulin therapy
18. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
19. Significant weight gain with rezulin therapy
20. Pulmonary edema associated with troglitazone therapy
21. Troglitazone-induced pulmonary edema
22. Sulfonylureas and ischaemic preconditioning: A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
23. Comparative tolerability profiles of oral antidiabetic drugs
24. Use of dexamethasone in treatment of insulin lipoatrophy
25. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ)
26. Ileus: A rare side effect of acarbose
27. Potentially lethal ileus associated with acarbose treatment for NIDDM
28. Adverse effects of exogenous insulin
29. "Glitazones," a prospect for non-insulin-dependent diabetes
30. The renal metabolism of insulin
31. Insulin-induced lipoatrophy: Evidence for an immune pathogenesis
32. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
33. Insulin-induced cardiac failure
34. Effect of thiazolidinediones on expression of UCP 2 and adipocyte markers in human PAZ6 adipocytes